Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780132 | 1.00 | HTR1A (0.48) | HTR1ASLC6A4CA2HDAC3HDAC4 | |
| SCHEMBL6783163 | 1.00 | HTR1A (0.48) | HTR1ASLC6A4CA2HDAC3HDAC4 | |
| SCHEMBL5762725 | 0.82 | HTR2C (0.51) | HTR1ASLC6A4CA2HDAC3HDAC4 | |
| SCHEMBL8184082 | 0.82 | CA2 (0.48) | HTR1ASLC6A4CA2HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL7095913 | 0.81 | HTR2C (0.52) | HTR1ASLC6A4CA2HDAC3HDAC4 | |
| SCHEMBL5759587 | 0.80 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL5757169 | 0.80 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL7505264 | 0.80 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL7118568 | 0.80 | HTR1A (0.47) | HTR1ASLC6A4CA2 | |
| SCHEMBL5760790 | 0.80 | HTR1A (0.47) | HTR1ASLC6A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367818-B1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONO-AMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | INITIATOR PHARMA AS (DK) | 2018-07-25 | — | — | EP | disclosed |
| US-6835733-B2 | Useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from tobacco or nicotine. | ELI LILLY AND COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20030130513-A1 | Useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from tobacco or nicotine. | ELI LILLY AND COMPANY | 2003-07-10 | — | — | US | disclosed |
| EP-1242419-A1 | AZABICYCLO 3.2.1]OCTANE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046187-A1 | AZABICYCLO[3.2.1]OCTANE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130513-A1 | Useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from tobacco or nicotine. | CHRNA5, CHRNA1, CHRNA2 | HTR1A 15/4885SLC6A4 96/4885CA2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.